SFX by Ex Libris Inc.

Title:	The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator
Source:	Science [0036-8075] Fontanilla, D yr:2009

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Cakic, V. "Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users." Drug and Alcohol Dependence 111.1-2 (2010): 30-37.
description	2.	Jacob, David E S. "Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine." Medical Hypotheses 64.5 (2005): 930-7.
description	3.	Strassman, R J J. "Human psychopharmacology of N,N-dimethyltryptamine." Behavioural Brain Research 73.1-2 (1996): 121-4.
description	4.	Santos, R. "Pharmacology of ayahuasca administered in two repeated doses." Psychopharmacology 219.4 (2012): 1039-1053.
description	5.	Wallach, J. V. "Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception." Medical hypotheses 72.1 (2008): 91-4.
description	6.	Strassman, R J J. "Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans." Biological Psychiatry 39.9 (1996): 784-95.
description	7.	Cozzi,, Nicholas V., Nicholas V. "Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter." Journal of Neural Transmission 116.12 (2009): 1591-1599.
description	8.	Fábregas, Josep M. "Assessment of addiction severity among ritual users of ayahuasca." Drug and Alcohol Dependence 111.3 (2010): 257-261.
description	9.	Bouso, Jos C. "Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study." PLoS ONE 7.8 (2012).
description	10.	Winstock AR, Adam R. "Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample." Journal of psychopharmacology 28.1 (2013): 49-54.
description	11.	González-Maeso, J. "Psychedelics and schizophrenia." Trends in Neurosciences 32.4 (2009): 225-232.
description	12.	Boone, K B B. "Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil." Journal of nervous and mental disease 184.2 (1996): 86-94.
description	13.	Strassman, R J R. "Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects." Archives of general psychiatry 51.2 (1994): 85-97.
description	14.	Bouso, José C. "Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users." Psychopharmacology 230.6 (2013): 415-424.
description	15.	Nichols, David E. Pharmacology & therapeutics 101.2 (2004): 131-81.
description	16.	Riba, J. "Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant." Psychopharmacology 186.1 (2006): 93-8.
description	17.	Riba, J. "Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers." British journal of clinical pharmacology 53.6 (2002): 613-628.
description	18.	Fantegrossi, William E E. "The behavioral pharmacology of hallucinogens." Biochemical Pharmacology 75.1 (2007): 17-33.
description	19.	San Rafael, C. "DMT: The Spirit Molecule: A Doctor’s Revolutionary Research Into the Biology of Near-Death and Mystical Experiences." The American journal of psychiatry 159.8 (2002): 1448-1449.
description	20.	Gable, Robert S S. "Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids." Addiction 102.1 (2006): 24-34.